Immunotherapy Combo Shows Early Efficacy for Malignant Mesothelioma – Surviving Mesothelioma
Surviving Mesothelioma |
Immunotherapy Combo Shows Early Efficacy for Malignant Mesothelioma
Surviving Mesothelioma AstraZeneca's immunotherapy drug tremelimumab may still have a chance as a novel mesothelioma treatment, even though an international clinical trial completed last year found that it did not extend mesothelioma survival. In a new study published in The … |
